Supplement contains meth-like compound
A widely available workout supplement called Craze contains an unlisted compound that is chemically similar to methamphetamine, according to a study published in the journal _Drug Testing and Analysis. _The supplement, made by Driven Sports Inc., is marketed as a way to improve workout performance, and lists extract from dendrobium orchids on the label. But, several athletes who reported taking Craze failed drug urine tests.
For the study, researchers analyzed three samples of Craze from different vendors. Two of the samples were analyzed by NSF International, a company that certifies supplements, and the other was tested at the Netherlands National Institute for Public Health.
Researchers say that instead of finding anything from an orchid, it contained an unlisted cousin of methamphetamine called N,a- DEPEA. The effects of this drug on people are not known, but researchers say the active part of the compound appears structurally similar to the active part of meth, which gives a clue to how it affects the body.
Researchers say it’s possible that manufacturers are purchasing the compound that’s labeled at dendrobium as a “cover.” The Food and Drug Administration was informed in May, but has not yet alerted the public or sent a warning letter to the company.
NEXT: Columbus discovers tobacco: Oct. 15, 1492
Sourced from: livescience, Workout Supplement Contains Meth-Like Compound
Published On: Oct 17, 2013
Urine test could find blood clots early
Blood clots can form in anyone who sits on a plane for a long time, is confined to bed while recovering from surgery, or takes certain medications. And, unfortunately, there’s isn’t an easy way to diagnose these clots until they break free and potentially cause a major medical event, such as a stroke or heart attack. But new technology from MIT may soon make it possible to detect clots through a simple, non-invasive urine test.
The new diagnostic tool, recently described in the journal ACS Nano, relies on nanoparticles that detect the presence of thrombin, a key blood-clotting factor. Sangeeta Bhatia, senior author of the paper, notes such a system could be used to monitor patients who are at high risk for blood clots.
The new technology consists of iron oxide nanoparticles–which the Food and Drug Administration–has approved for human use, coated with peptides (short proteins) that are specialized to interact with an enzyme called thrombin. After being injected into mice, the nanoparticles traveled throughout animals’ bodies. When the particles encountered thrombin, the thrombin cut the peptides at a specific location, releasing fragments that were then excreted in the animals’ urine. Once the urine was collected, the protein fragments could be identified by treating the sample with antibodies specific to peptide tags included in the fragments. The researchers showed that the amount of these tags found in the urine was directly proportional to the level of blood clotting in the mice’s lungs.
The researchers envision two possible applications for this kind of test. One is to screen patients who come to the emergency room complaining of symptoms that might indicate a blood clot, and the other is to monitor patients who are at high risk for a clot, such as people who have to spend a lot of time in bed recovering from surgery. Sangeeta Bhatia, co-author of the study, plans to launch a company to commercialize the technology, with funding from M.I.T’s Deshpande Center for Technological Innovation.
NEXT: How cold weather affects the body
Sourced from: Science Daily, Finding Blood Clots Before They Wreak Havoc
Published On: Oct 17, 2013